Evidence map›Paper›PMID 28592171›Full record

ReviewExperimental biology and medicine (Maywood, N.J.)2017

Next generation human skin constructs as advanced tools for drug development.

H E Abaci, Zongyou Guo, Yanne Doucet, Joanna Jacków, Angela Christiano

Open access · greenAbstract readReview
In one paragraph

Review in Experimental biology and medicine (Maywood, N.J.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 99 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Cellular Pathogenesis of Chemotherapy-Induced Peripheral Neuropathy: Insights FromFrontiers in pain research (Lausanne, Switzerland) · 2022
    Review
  16. Keratins as an Inflammation Trigger Point in Epidermolysis Bullosa Simplex.International journal of molecular sciences · 2021
    Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

H E Abaci1 Department of Dermatology, Columbia University Medical Center, New York, NY 10032, USA.
Zongyou Guo1 Department of Dermatology, Columbia University Medical Center, New York, NY 10032, USA.
Yanne Doucet1 Department of Dermatology, Columbia University Medical Center, New York, NY 10032, USA.
Joanna Jacków1 Department of Dermatology, Columbia University Medical Center, New York, NY 10032, USA.
Angela Christiano1 Department of Dermatology, Columbia University Medical Center, New York, NY 10032, USA.
Columbia University Irving Medical Center · US

Funding

Tissue Chips for Rare Disease: Adding Timothy Syndrome to the HeLIVaSkCa platformUH3EB017103 · NIBIB · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI VUNJAK-NOVAKOVIC, GORDANA · 2014 to 2016
$7.1M
Multi-tissue platform for modeling systemic pathologiesUG3EB025765 · NIBIB · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI VUNJAK-NOVAKOVIC, GORDANA · 2017 to 2019
$2.8M
DOCTORAL STUDIES IN MOLECULAR BIOPHYSICST32GM008271 · NIGMS · WESLEYAN UNIVERSITY · PI BEVERIDGE, DAVID LEWIS · 1988 to 2015
$1.8M
Bioprinting 3D skin for patient-specific drug discovery in inflammatory skin diseases.U18TR002305 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CHRISTIANO, ANGELA M · 2017 to 2018
$1.3M
NCATS NIH HHS U18 TR002305NIBIB NIH HHS UG3 EB025765NIBIB NIH HHS UH3 EB017103NIGMS NIH HHS T32 GM008271
6 · The paper itself

Abstract

Many diseases, as well as side effects of drugs, manifest themselves through skin symptoms. Skin is a complex tissue that hosts various specialized cell types and performs many roles including physical barrier, immune and sensory functions. Therefore, modeling skin in vitro presents technical challenges for tissue engineering. Since the first attempts at engineering human epidermis in 1970s, there has been a growing interest in generating full-thickness skin constructs mimicking physiological functions by incorporating various skin components, such as vasculature and melanocytes for pigmentation. Development of biomimetic in vitro human skin models with these physiological functions provides a new tool for drug discovery, disease modeling, regenerative medicine and basic research for skin biology. This goal, however, has long been delayed by the limited availability of different cell types, the challenges in establishing co-culture conditions, and the ability to recapitulate the 3D anatomy of the skin. Recent breakthroughs in induced pluripotent stem cell (iPSC) technology and microfabrication techniques such as 3D-printing have allowed for building more reliable and complex in vitro skin models for pharmaceutical screening. In this review, we focus on the current developments and prevailing challenges in generating skin constructs with vasculature, skin appendages such as hair follicles, pigmentation, immune response, innervation, and hypodermis. Furthermore, we discuss the promising advances that iPSC technology offers in order to generate in vitro models of genetic skin diseases, such as epidermolysis bullosa and psoriasis. We also discuss how future integration of the next generation human skin constructs onto microfluidic platforms along with other tissues could revolutionize the early stages of drug development by creating reliable evaluation of patient-specific effects of pharmaceutical agents. Impact statement Skin is a complex tissue that hosts various specialized cell types and performs many roles including barrier, immune, and sensory functions. For human-relevant drug testing, there has been a growing interest in building more physiological skin constructs by incorporating different skin components, such as vasculature, appendages, pigment, innervation, and adipose tissue. This paper provides an overview of the strategies to build complex human skin constructs that can faithfully recapitulate human skin and thus can be used in drug development targeting skin diseases. In particular, we discuss recent developments and remaining challenges in incorporating various skin components, availability of iPSC-derived skin cell types and in vitro skin disease models. In addition, we provide insights on the future integration of these complex skin models with other organs on microfluidic platforms as well as potential readout technologies for high-throughput drug screening.

Indexed as

Drug DiscoveryHumansInduced Pluripotent Stem CellsLab-On-A-Chip DevicesMicrochip Analytical ProceduresMicrofluidicsRegenerative MedicineSkinSkin DiseasesTissue Engineeringdrug testingmicrophysiological systemsSkin constructsskin-on-a-chip

Identifiers

PMID28592171
PMCPMC5786367
OpenAlexW2622369378

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.